LEIDEN, NETHERLANDS--(Marketwire - August 11, 2010) - Dutch biopharmaceutical company
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) today announced
that it will release its financial results for the second quarter 2010 on
Tuesday August 17, 2010 at 07:45 AM Central European Time (CET).
At 2:00 PM Central European Time (CET), Crucell's management will conduct a
conference call, which will also be webcast. To participate in the
conference
call, please call one of the following telephone numbers 15 minutes prior
to the
event:
+44 20 7806 1956 for the UK;
+1 212 444 0413 for the US; and
+3120 707 5511 for the Netherlands
Following a presentation of the results, the lines will be opened for a
question
and answer session.
The live audio webcast can be accessed via the homepage of Crucell's
website at
www.crucell.com and will be archived and available for replay following the
event.
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL) (SWISS: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115
million
vaccine doses in more than 100 countries around the world, with the fast
majority of doses (97%) going to developing countries. Crucell is one of
the
major suppliers of vaccines to UNICEF and the developing world. Crucell was
the
first manufacturer to launch a fully-liquid pentavalent vaccine called
Quinvaxem®. Quinvaxem® protects against five important childhood
diseases and
over 130 million doses have been sold since its launch in 2006 in more than
50
GAVI countries. Through Quinvaxem® and its innovation, Crucell has
become a
major partner in protecting children in developing countries. Crucell's
core
portfolio also includes a vaccine against hepatitis B and a virosome-
adjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such as an
oral
anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad development
pipeline,
with several product candidates based on its unique PER.C6® production
technology. The Company licenses its PER.C6® technology and other
technologies
to the biopharmaceutical industry. Important partners and licensees include
Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL
and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden,
Switzerland, UK, the USA and Vietnam. The Company employs over 1200 people.
For
more information, please visit www.crucell.com.
Forward-looking statements
This press release contains forward-looking statements that involve
inherent
risks and uncertainties. We have identified certain important factors that
may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors
please
refer to our Form 20-F, as filed with the US Securities and Exchange
Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company
prepares
its financial statements under International Financial Reporting Standards
(IFRS).
For further information please contact Crucell:
Oya Yavuz
Vice President Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
ir@crucell.com
www.crucell.com
[HUG#1437148]
PDF file:
http://hugin.info/132631/R/1437148/381999.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Crucell N.V. via Thomson Reuters ONE
